CABG

A global health problem

Today an estimated 82 million Americans suffer from one or more types of cardiovascular disease (CVD). It is the cause of 1 out of every 6 deaths in the United States, and every year well over 395,000 Americans undergo coronary artery bypass surgery to mitigate its effects. The total economic burden of CVD is staggering, exceeding $286.6 billion in 2007.1

In 28 Member Countries of the European Union (EU), the burden of CVD is also significant. It is the leading cause of death, and each year it contributes to over 2.0 million deaths within the European community. The total economic burden of CVD to the EU economy is estimated at €192 billion a year.2

82 Million - Number of Americans with CVD

Number of Americans
with CVD

Heart Disease causes 1 out of every 6 deaths in the US

Heart Disease causes
1 out of every 6
deaths in the US

395K - Number of Americans that annually undergo CABG procedures

Number of Americans
that annually undergo
CABG procedures

$286.6 billion - U.S. Economic burden of CVD (2007)

U.S. Economic burden
of CVD (2007)

Significant treatment innovation

Kips Bay Medical is dedicated to providing superior therapeutic technologies to the cardiac surgeon. Our eMesh technology represents an innovative platform designed to advance, refine, and improve cardiac surgery. The company’s first commercial product is the eSVS Mesh- a metal alloy (nitinol) prosthesis designed to control key physical parameters of saphenous vein grafts used in coronary artery bypass surgery. This allows more physiological remodeling of the saphenous vein, an advancement which we believe can help maintain patency of saphenous vein grafts. We believe the eSVS Mesh represents the future of CABG surgery – a simple, easy-to-use device designed to enhance the surgeon’s ability to optimize patient outcomes and potentially reduce costly and complicated reinterventions.

mesh

1 American Heart Association—Heart Disease and Stroke Update
2 European Cardiovascular Disease Statistics: 2008 Edition